In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for SCENESSE® (afamelanotide 16mg) by three months
Recent Posts
SCENESSE® registration dossier submitted in Australia
CLINUVEL initiates the registration process under priority review for its new pharmaceutical...
Read More
Notice of Change of Interests of Substantial Holder
Form 604 – Notice of change of interests of substantial holder...
Read More